Establishment Labs Holdings (ESTA) Misses Q4 EPS by $1.39
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Establishment Labs Reports Fourth Quarter and Full Year 2021 Financial Results; Record Fourth Quarter Revenue of $35.3 Million
March 1, 2022 8:00 AM ESTSANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided initial 2022 guidance.
Fourth Quarter Highlights and Outlook
Fourth quarter worldwide sales of $35.3 million, an increase of 31.0% year-over-year and a new quarterly record; consistent with preannouncement on January 10, 2022. 2022 guidance of $155 million to $165 million, an increase... More